DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Thursday. They presently have a $12.00 price objective on the stock.

Other analysts have also issued research reports about the company. Dawson James restated a “buy” rating on shares of DelMar Pharmaceuticals in a research note on Tuesday, August 8th. Maxim Group reiterated a “buy” rating and set a $11.00 target price on shares of DelMar Pharmaceuticals in a research note on Friday, June 23rd.

DelMar Pharmaceuticals (NASDAQ:DMPI) traded down 4.18983% during mid-day trading on Thursday, reaching $0.85501. The company’s stock had a trading volume of 764,808 shares. The stock’s market cap is $18.43 million. DelMar Pharmaceuticals has a 52-week low of $0.80 and a 52-week high of $6.00. The company has a 50 day moving average of $1.15 and a 200-day moving average of $2.19.

TRADEMARK VIOLATION WARNING: “HC Wainwright Reaffirms Buy Rating for DelMar Pharmaceuticals, Inc. (DMPI)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at

An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Sabby Management LLC purchased a new position in shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 645,390 shares of the company’s stock, valued at approximately $1,484,000. Sabby Management LLC owned approximately 4.79% of DelMar Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 13.74% of the company’s stock.

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.